No Data
Pulike Biological Engineering, Inc. (603566.SH): Mirtazapine ointment has obtained a new veterinary drug registration certificate.
Pulike biological engineering,inc. (603566.SH) announced that the company and its wholly-owned subsidiary Luoyang Huizhong Veterinary Medicine Co., Ltd., Luoyang Huizhong Animal...
Pulike Biological Engineering, Inc. (603566.SH): Actively promoting the layout of companion animal related products.
Gelonghui reported on November 26 that pulike biological engineering, inc. (603566.SH) stated on the investor interaction platform that the company's main business products have covered the prevention and treatment of animal diseases in livestock, poultry, and pets; for a long time, the company has adhered to a "full-category" global strategy, actively promoting the layout of companion animal-related products while improving the layout of pig and poultry products through independent research and development and technical cooperation.
Pulike Biological Engineering, Inc. (603566.SH): Currently, there are no plans to acquire Yichong Health.
Gelonghui November 26th | Pulike Biological Engineering,Inc.(603566.SH) stated on the investor interaction platform that Yichong Health and Pulike Biological Engineering,Inc. are controlled by the same controller, affiliated companies of the company, but the company does not hold shares in Yichong Health. Yichong Health is committed to building a first-class chain of pet hospitals, improving the standardization level and service quality of the pet diagnosis and treatment industry. The company currently has no plans to acquire Yichong Health.
Earnings Troubles May Signal Larger Issues for Pulike Biological Engineering (SHSE:603566) Shareholders
pulike biological engineering,inc. (603566.SH): Cumulatively repurchased 1.2% of shares, company completes repurchase
Gelonghui, November 1st | Pulike Biological Engineering, Inc. (603566.SH) announced that on November 1, 2024, the company completed the repurchase, actually repurchasing 4,142,900 shares of the company's stock, accounting for 1.20% of the total share capital of the company. The highest repurchase price was 22.48 yuan/share, the lowest price was 11.66 yuan/share, and the average repurchase price was 14.56 yuan/share. The total amount paid was 60,328,181 yuan (excluding transaction costs).
Placo 2024 Third Quarter Report
Benign Growth For Pulike Biological Engineering, Inc. (SHSE:603566) Underpins Stock's 27% PlummetNo Data
No Data
